Growth Hormone (GH), GH antagonists, and GH receptor “knockouts”; of mice & men
James Kopchick, PhD
Distinguished Professor and Goll-Ohio Eminent Scholar
Edison Biotechnology Institute
Dept. of Biomedical Sciences, HCOM
Ohio University
James Kopchick, PhD, is an internationally recognized leader in the growth hormone field. He is the Goll-Ohio Eminent Scholar and Distinguished Professor in Molecular Biology at Ohio University in Athens, Ohio. His PhD in Biomedical Sciences was awarded in 1980 by the University of Texas. Dr. Kopchick and his group were the first to discover and characterize GH receptor antagonists, an accomplishment for which he and Ohio University were awarded several US and European patents. Dr. Kopchick was instrumental in founding a company, Sensus, which applied his research to the development of an FDA approved drug for acromegaly. He has published more than 300 scientific articles and serves or has served on the Editorial Boards of Endocrinology, Molecular Endocrinology, GH & IGF-1 Research, Pituitary, Polish Journal of Endocrinology, and The Journal of Biological Chemistry. He is President of the Growth Hormone Research Society and has received many awards including the British Endocrine Society Transatlantic Award.
At the conclusion of this program, participants should understand:
1. Discovery and clinical use of GH antagonists
2. GH and its involvement in aging and longevity
3. Background to GH action
Event-Date:
Friday, March 13, 2015 - 8:00am to 9:00am
Event-Location:
4051 UC Medical Sciences Building (MSB)
Event Category:
Regularly Scheduled Seminars
Event-Contact-Person:
Jo Quivers
Event-Contact-Email:
quiverje@uc.edu